demyelinating

MOG (35-55) mouse, rat is a minor component of the central nervous system myelin with high brain specificity and strong immunogenicity. It can induce T and B cell responses, trigger relapsing-remitting neurological disorders with plaque-like demyelination, and is commonly used for inducing experimental autoimmune encephalomyelitis (EAE) models.

Stemazole is a novel small molecule human stem/progenitor cell proliferation activator that promotes the survival of human embryonic stem cells and maintains stemness, and promotes the survival of oligodendrocyte precursor cells in vitro. Stemazole significantly increased cell survival and clone formation in a dose-dependent manner, reduced apoptosis, and promoted recovery of motor dysfunction and myelin repair. Stemazole can be used as a therapeutic agent in demyelinating disorders, promoting OPC survival in vitro and regeneration in vivo.

Natalizumab is a recombinant humanized monoclonal antibody and a humanized monoclonal antibody inhibitor that selectively targets α4 integrin (CD49d). Natalizumab binds to the α4β1 heterodimer and blocks its interaction with vascular cell adhesion molecule 1. Natalizumab also prevents lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses, and is used in the study of relapsing-remitting multiple sclerosis and Crohn’s disease. Natalizumab possesses anti-inflammatory and immunomodulatory activity, inhibiting the adhesion, retention, and transendothelial migration of immune cells, and reducing the infiltration of inflammatory cells into the central nervous system or affected sites. Natalizumab is also being studied for autoimmune or inflammation-related diseases such as B-cell lymphoma and non-infectious uveitis.

ARN-6039, an orally available inverse agonist of RORγ, targets Autoimmune Neuroinflammatory Demyelinating Disease. Its efficacy was demonstrated in a RORγ-activated IL-17A Prom/LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 release from CD4+T cell assays (220 nM).

ASN04885796 (compound IV) is a neuroprotective, specific GPR17 agonist with an EC50=2.27 nM for GPR17-mediated GTPγS binding and can be used to study neurodegenerative diseases such as cerebral ischemia and demyelinating diseases.

ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.

MOG peptide (35-55), mouse, rat acetate is a minor component of central nervous system myelin sheaths. It possesses encephalitis-inducing activity, capable of stimulating CD4⁺ T cell proliferation and Th1-type immune responses, thereby triggering relapsing-remitting demyelinating diseases. It is commonly used to establish experimental autoimmune encephalomyelitis (EAE) models.

Divozilimab (BCD-132) is a humanized monoclonal antibody that targets CD20. Divozilimab (BCD-132) is utilized in multiple sclerosis research and serves as a valuable molecular tool for investigating CD20-mediated immune mechanisms, B-cell biology, and neuroimmunological processes associated with demyelinating disorders.

PLP (180-199), an active biological peptide comprising amino acids 180-199 of myelin proteolipid protein (PLP)—the predominant myelin protein in the central nervous system (CNS)—is utilized in research focused on multiple sclerosis (MS), a chronic inflammatory demyelinating condition of the CNS.

NRMA-8 is a small-molecule nuclear receptor modulator capable of penetrating the brain. It holds potential for research into central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson's disease, demyelinating diseases, and glioblastoma.

CAQK peptide specifically binds to injured mouse brain tissue and targets demyelinating areas without affecting healthy tissue. It interacts with a proteoglycan complex that is upregulated in brain injuries, making it useful for drug delivery applications. Additionally, CAQK peptide can penetrate the blood-brain barrier [1] [2].

S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. It is utilized to develop models of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is also studied in the context of autoimmune-mediated neuritis.